Subsidiary Aprogen Biologics to issue 50.8B KRW CB
에이프로젠
007460
Signal Score
Historical Avg Return (5d)
+0.72%
Data Coverage
100%n=2249
Risk-adjusted indicator based on 2249 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • Total Convertible Bond Amount: 50.8 billion KRW
- • Conversion Price: 3,778 KRW/Share
4 more figures — Starter & Pro plans
AI Analysis Summary
Aprogen Biologics, a subsidiary of Aprogen, Inc., has decided to issue 50.8 billion KRW in private placement convertible bonds (CBs) to repay existing debt. The conversion price is 3,778 KRW per share, potentially issuing 13,446,267 new shares, representing a 93.30% dilution relative to current outstanding shares. Including previously issued CBs, the total potential dilution could reach 262.78%. The CBs carry a 2% surface interest rate and a 4% maturity interest rate, with a maturity date of June 4, 2029. Bondholders have a put option starting December 4, 2027, with varying early redemption rates. This significant dilution, primarily for debt repayment, is a negative for existing shareholders.
Risk Factors
Pro plan
Access Full Korean Market Signal Analytics
✔ AI-parsed DART filing classification & scoring
✔ Real-time event impact indicators
✔ Price reaction & historical pattern data
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.